文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Betibeglogene autotemcel基因治疗输血依赖型重型基因型β地中海贫血患者(HGB-212):一项非随机、多中心、单臂、开放标签、单剂量3期试验

Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial.
PubMed 文献 · Lancet · 2024-11-08

HGB-212是一项非随机、多中心、单臂、开放标签3期试验,评估beti-cel在输血依赖型β地中海贫血患者中的疗效与安全性。18例接受输注的患者中,16例(89%)达到并维持输血不依赖(估计效应量89.9%[95%CI 65.3-98.6])。所有患者至少发生1例不良事件,无归因于beti-cel的严重不良事件,无死亡。

要点

  • 18例接受beti-cel输注的患者中,16例(89%)达到并维持输血不依赖至末次随访。
  • 所有患者至少发生1例不良事件,无归因于beti-cel的严重不良事件,无死亡。
  • 患者正接受总计15年随访,以评估输血不依赖的持久性和长期安全性。

核心结论

  • 这些数据表明beti-cel可使携带导致重型β地中海贫血基因型(β0/β0、β0/β+IVS-I-110或β+IVS-I-110/β+IVS-I-110)的患者达到输血不依赖。
  • Beti-cel为重型输血依赖型β地中海贫血患者提供了达到接近正常血红蛋白水平的可能,并提供了一种无需异基因造血干细胞移植风险和局限性的潜在治愈选择。
  • 患者正接受总计15年随访,以评估输血不依赖的持久性和beti-cel的长期安全性特征。

研究设计与样本

  • HGB-212是一项在法国、德国、希腊、意大利、英国和美国8个中心开展的非随机、多中心、单臂、开放标签、单剂量3期研究。
  • 纳入标准为:β0/β0、β0/β+IVS-I-110或β+IVS-I-110/β+IVS-I-110基因型,临床稳定的输血依赖型β地中海贫血,且入组前2年内接受浓缩红细胞输注史至少100 mL/kg/年或每年至少8次浓缩红细胞输注。
  • 患者在接受HSPC动员和基于白消安的药代动力学调整的清髓性预处理后,输注beti-cel并随访24个月。
  • 主要疗效结局为输血不依赖,定义为在不接受浓缩红细胞输注的情况下,加权平均血红蛋白水平≥9 g/dL持续12个月或以上;主要结局在所有接受beti-cel输注的患者(移植人群)中测量。
  • 安全性在所有启动研究治疗的患者(意向性治疗人群)中评估;患者有资格参加正在进行的13年长期随访研究LTF-303(总计15年)。

主要发现

  • 2017年6月8日至2020年3月12日,筛选20例患者,1例不符合条件,1例在HSPC动员和清髓性预处理前撤回知情同意。
  • 接受beti-cel的18例患者中,10例(56%)为男性,8例(44%)为女性;13例(72%)在知情同意时年龄小于18岁,5例(28%)年龄大于18岁。
  • 12例(67%)患者为β0/β0基因型,3例(17%)为β0/β+IVS-I-110,3例(17%)为β+IVS-I-110/β+IVS-I-110。
  • 截至2023年1月30日,所有患者均入组长期随访研究,中位随访47.9个月(范围23.8-59.0)。
  • 全部18例患者均可评估输血不依赖,16例(89%)达到并维持输血不依赖至末次随访(估计效应量89.9%[95%CI 65.3-98.6]);所有患者beti-cel输注后至少发生1例不良事件,无归因于beti-cel的严重不良事件,无死亡。

关键数值与推荐

  • 主要疗效结局输血不依赖定义为加权平均血红蛋白水平≥9 g/dL且无需浓缩红细胞输注持续12个月或以上。
  • 18例可评估患者中16例(89%)达到并维持输血不依赖至末次随访,估计效应量89.9%(95%CI 65.3-98.6)。
  • 纳入的基因型为β0/β0、β0/β+IVS-I-110或β+IVS-I-110/β+IVS-I-110。
  • 入组前2年内浓缩红细胞输注史至少100 mL/kg/年或每年至少8次输注。
  • 预处理为基于白消安的药代动力学调整的清髓性预处理。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transfusion-dependent β-thalassaemia (TDT) is a severe disease, resulting in lifelong blood transfusions, iron overload, and associated complications. Betibeglogene autotemcel (beti-cel) gene therapy uses autologous haematopoietic stem and progenitor cells (HSPCs) transduced with BB305 lentiviral vector to enable transfusion independence. METHODS: HGB-212 was a non-randomised, multicentre, single-arm, open-label, phase 3 study of beti-cel in patients with TDT conducted at eight centres in France, Germany, Greece, Italy, the UK, and the USA. Patients with β0/β0, β0/β+IVS-I-110, or β+IVS-I-110/β+IVS-I-110 genotypes, clinically stable TDT, and a transfusion history of at least 100 mL/kg per year of packed red blood cells (pRBCs) or at least eight transfusions of pRBCs per year in the 2 years before enrolment were eligible for participation. After undergoing HSPC mobilisation and busulfan-based, pharmacokinetic-adjusted myeloablative conditioning, patients were infused with beti-cel and followed up for 24 months. The primary efficacy outcome was transfusion independence, defined as weighted average haemoglobin level of 9 g/dL or above without pRBC transfusions for 12 or more months. The primary outcome was measured in all patients who received an infusion of beti-cel (transplant population); safety was evaluated in all patients who initiated study treatment (intention-to-treat population). Patients were eligible to enrol in the ongoing 13-year long-term follow-up study (for a total of 15 years), LTF-303 (registered at ClinicalTrials.gov, NCT02633943). This trial, HGB-212, was registered at ClinicalTrials.gov (NCT03207009), and is complete. FINDINGS: From June 8, 2017, to March 12, 2020, 20 patients were screened for eligibility. One patient was ineligible and one withdrew consent before HSPC mobilisation and myeloablative conditioning. Of the 18 patients who received beti-cel, ten (56%) were male and eight (44%) were female; 13 (72%) were younger than 18 years at the time of informed consent, and five (28%) were older than 18 years. 12 (67%) patients had β0/β0 genotypes, three (17%) had β0/ β+IVS-I-110, and three (17%) had β+IVS-I-110/β+IVS-I-110. As of Jan 30, 2023, all patients enrolled in the long-term follow-up study and the median follow-up was 47·9 months (range 23·8-59·0). All 18 patients were evaluable for transfusion independence, with 16 (89%) of 18 reaching and maintaining transfusion independence to last follow=up (estimated effect size 89·9% [95% CI 65·3-98·6]). All patients had at least one adverse event after beti-cel infusion. There were no serious adverse events considered to be related to beti-cel, and no deaths. INTERPRETATION: These data demonstrate that beti-cel can allow patients with genotypes that cause severe β-thalassaemia (β0/β0, β0/β+IVS-I-110, or β+IVS-I-110/β+IVS-I-110) to reach transfusion independence. Beti-cel offers the potential to attain near-normal haemoglobin levels for those with severe forms of TDT, and a potentially curative option without the risks and limitations of allogeneic HSPC transplantation. Patients are being followed up for a total of 15 years to assess the durability of transfusion independence and long-term safety profile of beti-cel. FUNDING: Bluebird Bio, Somerville, MA, USA.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Kwiatkowski JL, Walters MC, Hongeng S, et al. Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial. Lancet. 2024. PMID: 39527960. doi:10.1016/S0140-6736(24)01884-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。